Justin Gainor
Justin Gainor
Massachusetts General Hospital
Verified email at partners.org
Title
Cited by
Cited by
Year
Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer
J Brahmer, KL Reckamp, P Baas, L Crinò, WEE Eberhardt, ...
New England Journal of Medicine 373 (2), 123-135, 2015
62182015
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ...
The lancet oncology 12 (11), 1004-1012, 2011
10162011
The ALK inhibitor ceritinib overcomes crizotinib resistance in non–small cell lung cancer
L Friboulet, N Li, R Katayama, CC Lee, JF Gainor, AS Crystal, ...
Cancer discovery 4 (6), 662-673, 2014
6772014
Molecular mechanisms of resistance to first-and second-generation ALK inhibitors in ALK-rearranged lung cancer
JF Gainor, L Dardaei, S Yoda, L Friboulet, I Leshchiner, R Katayama, ...
Cancer discovery 6 (10), 1118-1133, 2016
6402016
EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non–small cell lung cancer: a retrospective analysis
JF Gainor, AT Shaw, LV Sequist, X Fu, CG Azzoli, Z Piotrowska, ...
Clinical cancer research 22 (18), 4585-4593, 2016
6392016
Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled …
H Rizvi, F Sanchez-Vega, K La, W Chatila, P Jonsson, D Halpenny, ...
Journal of Clinical Oncology 36 (7), 633, 2018
6342018
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ...
The Lancet 395 (10241), 1907-1918, 2020
6132020
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
AS Crystal, AT Shaw, LV Sequist, L Friboulet, MJ Niederst, EL Lockerman, ...
Science 346 (6216), 1480-1486, 2014
5772014
STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma
F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ...
Cancer discovery 8 (7), 822-835, 2018
4942018
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non–small cell lung cancer
JF Gainor, AM Varghese, SHI Ou, S Kabraji, MM Awad, R Katayama, ...
Clinical cancer research 19 (15), 4273-4281, 2013
4552013
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
LV Sequist, RS Heist, AT Shaw, P Fidias, R Rosovsky, JS Temel, ...
Annals of Oncology 22 (12), 2616-2624, 2011
3912011
Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F
AT Shaw, L Friboulet, I Leshchiner, JF Gainor, S Bergqvist, A Brooun, ...
New England Journal of Medicine 374 (1), 54-61, 2016
3702016
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
AT Shaw, E Felip, TM Bauer, B Besse, A Navarro, S Postel-Vinay, ...
The Lancet Oncology 18 (12), 1590-1599, 2017
3692017
Acquired resistance to crizotinib from a mutation in CD74–ROS1
MM Awad, R Katayama, M McTigue, W Liu, YL Deng, A Brooun, ...
New England Journal of Medicine 368 (25), 2395-2401, 2013
3412013
PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models
HY Zou, L Friboulet, DP Kodack, LD Engstrom, Q Li, M West, RW Tang, ...
Cancer cell 28 (1), 70-81, 2015
3152015
Novel targets in non-small cell lung cancer: ROS1 and RET fusions
JF Gainor, AT Shaw
The oncologist 18 (7), 865, 2013
3062013
Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer
JF Gainor, AT Shaw
Journal of clinical oncology 31 (31), 3987, 2013
2822013
A combinatorial strategy for treating KRAS-mutant lung cancer
E Manchado, S Weissmueller, JP Morris, CC Chen, R Wullenkord, ...
Nature 534 (7609), 647-651, 2016
2552016
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib
R Katayama, L Friboulet, S Koike, EL Lockerman, TM Khan, JF Gainor, ...
Clinical cancer research 20 (22), 5686-5696, 2014
2552014
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
EE Vokes, N Ready, E Felip, L Horn, MA Burgio, SJ Antonia, OA Frontera, ...
Annals of oncology 29 (4), 959-965, 2018
2462018
The system can't perform the operation now. Try again later.
Articles 1–20